OncoZenge (ONCOZ) Q2 2026 earnings summary

Executive summary

• Received full European regulatory approval for pivotal Phase III "BEAM-Pain" trial of BupiZenge; first patient enrolled July 7, with 12 of 150 patients recruited across five hospitals in Scandinavia.

• Triggered milestone payments from Molteni Farmaceutici (SEK 5.8m) and Sichuan Yangtian Bio-Pharmaceutical (SEK 15m, with SEK 5m received and SEK 10m pending).

• Announced a SEK 33.3m rights issue to secure funding for Phase III completion and MAA dossier development.

• BupiZenge targets pain relief for oral mucositis in cancer patients, addressing a significant unmet need and aiming to reduce opioid use.

Financial highlights

• Q2 2026 net sales: SEK 5,840k (Q2 2025: SEK 0k); H1 2026 net sales: SEK 5,840k (H1 2025: SEK 2,664k).

• Q2 2026 operating result: SEK -5,441k (Q2 2025: SEK -2,605k); H1 2026 operating result: SEK -12,433k (H1 2025: SEK -2,561k).

• Cash and cash equivalents as of June 30, 2026: SEK 749k (Dec 31, 2025: SEK 3,714k).

• Equity ratio as of June 30, 2026: 36.54% (Dec 31, 2025: 34.74%).

• Main expenses driven by increased R&D and clinical trial preparation.

Outlook and guidance

• Rights issue and pending investment tranches expected to secure liquidity for at least 12 months.

• Patient recruitment for Phase III ongoing, with readout expected late 2026 or early 2027 depending on recruitment pace.

• Focus on preparing MAA dossier to accelerate time to approval and royalties.